ClinicalTrials.gg
CompletedNCT01365507BOOST™Updated Mar 17, 2017Results posted

Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens

A Phase 3 interventional study of insulin degludec/insulin aspart in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 42 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-17.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
276
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.

Enrollment
41st of 70
276 · median 384
Started
2011
with 7 others
Phase 3
49 of 70
2 open now
Registered
21st of 70
by date
Lead sponsor
56 of 70
Novo Nordisk A/S

Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 41st largest by enrollment, is one of 8 that started in 2011, is one of 49 in phase 3, and was the 21st registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About insulin degludec

insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial is conducted in Asia and North America. The aim of this trial is to compare the efficacy and safety of insulin degludec/insulin aspart (IDegAsp) once daily in insulin-naïve subjects with type 2 diabetes mellitus when using two different titration algorithms (dose individually adjusted) as add-on to subject's ongoing treatment with metformin.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 276 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes (diagnosed clinically) for 24 weeks or longer prior to randomisation (visit 2)
  • Insulin naïve subjects (Allowed are: Previous short term insulin treatment no longer than or equal to 14 days in total; Treatment during hospitalisation or during gestational diabetes is allowed for periods longer than 14 days in total)
  • Current treatment: Metformin alone or metformin in any combination of 1 or 2 additional OADs (oral anti-diabetic drug) including an insulin secretagogue (sulfonylurea or glinide), dipeptidyl peptidase IV (DPP-IV) inhibitors, alpha-glucosidase inhibitors or thiazolidinediones (TZDs) - all with unchanged dosing for at least 12 weeks prior to randomisation (visit 2). Metformin dose, alone or in combination (including fixed combination), must be at least 1000 mg daily
  • (glycosylated ) 7.0-10.0% (both inclusive)
  • (Body Mass Index) below or equal to 45 kg/m\^2
  • Ability and willingness to adhere to the protocol including self measurement of plasma glucose

Exclusion criteria

Exclusion Criteria:

  • Treatment with GLP-1 (glucagon like peptide) receptor agonists within the last 12 weeks prior to randomisation (visit 2)
  • Recurrent severe hypoglycaemia (more than one severe hypoglycaemic event during the last 12 months) or hypoglycaemic unawareness as judged by the Investigator (trial physician)
  • Previous participation in this trial. Participation is defined as randomised. Re-screening is allowed once during the recruitment period
  • Known or suspected to trial products or related products
  • The receipt of any drug within 4 weeks prior to randomisation (visit 2)
  • Anticipated significant lifestyle changes during the study, e.g. shift work (including permanent night/evening shift workers) as well as highly variable eating habits
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
276 participants (actual)

Study arms

  • Experimental
    IDegAsp Simple

    Drug: insulin degludec/insulin aspart

  • Experimental
    IDegAsp Step wise

    Drug: insulin degludec/insulin aspart

Interventions

  • Druginsulin degludec/insulin aspart

    Drug pages: Insulin degludec · Insulin Aspart

    Insulin degludec/insulin aspart injected subcutaneously (under the skin) once daily. Dose individually adjusted.

    Also known as: IDegAsp

07

What researchers measure

Primary outcomes

  1. Change in Glycosylated Haemoglobin (HbA1c)

    Change from baseline in HbA1c after 26 weeks of treatment.

    Time frame: Week 0, week 26

Secondary outcomes

  1. Change in Fasting Plasma Glucose (FPG)

    Change from baseline in FPG after 26 weeks of treatment.

    Time frame: Week 0, week 26

  2. Rate of Treatment Emergent Adverse Events (AEs)

    Corresponds to rate of AEs per 100 patient years of exposure. Severity assessed by investigator. Mild: no or transient symptoms, no interference with subject's daily activities. Moderate: marked symptoms, moderate interference with subject's daily activities. Severe: considerable interference with subject's daily activities, unacceptable. Serious AE: AE that at any dose results in any of the following: death, a life-threatening experience, in-subject hospitalization/prolongation of existing hospitalisation, persistent/significant disability/incapacity/congenital anomaly/birth defect.

    Time frame: Week 0 to Week 26 + 7 days follow up

  3. Rate of Confirmed Hypoglycaemic Episodes

    Rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes were defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes were defined as able to treat her/himself and plasma glucose below 3.1 mmol/L.

    Time frame: Week 0 to Week 26 + 7 days follow up

  4. Rate of Nocturnal Confirmed Hypoglycaemic Episodes

    Rate of nocturnal confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes were defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes were defined as able to treat her/himself and plasma glucose below 3.1 mmol/L. Nocturnal hypoglycaemic episodes were defined as occurring between 00:01 and 05:59 a.m.

    Time frame: Week 0 to Week 26 + 7 days follow up

08

Results

Posted Nov 20, 2015

Participant flow

This trial was conducted at 38 sites in 6 countries: Malaysia, Mexico, South Korea, Thailand, Turkey and the United States (U.S.).

Participant flow — Overall Study
MilestoneIDegAsp SimpleIDegAsp Step Wise
Started136140
Exposed134140
Completed127131
Not completed99
Withdrew: Withdrawal criteria85
Withdrew: Unclassified14

Outcome measures

PrimaryChange in Glycosylated Haemoglobin (HbA1c)

Change from baseline in HbA1c after 26 weeks of treatment.

Time frame:
Week 0, week 26
Reported as:
Mean · percentage of glycosylated haemoglobin
Change in Glycosylated Haemoglobin (HbA1c)
percentage of glycosylated haemoglobinIDegAsp SimpleIDegAsp Step Wise
Change in Glycosylated Haemoglobin (HbA1c)-1.33 ± 1.03-1.09 ± 0.82
SecondaryChange in Fasting Plasma Glucose (FPG)

Change from baseline in FPG after 26 weeks of treatment.

Time frame:
Week 0, week 26
Reported as:
Mean · mmol/L
Change in Fasting Plasma Glucose (FPG)
mmol/LIDegAsp SimpleIDegAsp Step Wise
Change in Fasting Plasma Glucose (FPG)-2.99 ± 3.03-2.73 ± 2.91
SecondaryRate of Treatment Emergent Adverse Events (AEs)

Corresponds to rate of AEs per 100 patient years of exposure. Severity assessed by investigator. Mild: no or transient symptoms, no interference with subject's daily activities. Moderate: marked symptoms, moderate interference with subject's daily activities. Severe: considerable interference with subject's daily activities, unacceptable. Serious AE: AE that at any dose results in any of the following: death, a life-threatening experience, in-subject hospitalization/prolongation of existing hospitalisation, persistent/significant disability/incapacity/congenital anomaly/birth defect.

Time frame:
Week 0 to Week 26 + 7 days follow up
Reported as:
Number · Events/100 years of patient exposure
Rate of Treatment Emergent Adverse Events (AEs)
Events/100 years of patient exposureIDegAsp SimpleIDegAsp Step Wise
Adverse events (AEs)226342
Serious AEs213
Severe AEs33
Moderate AEs68112
Mild AEs155228
Fatal AEs00
SecondaryRate of Confirmed Hypoglycaemic Episodes

Rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes were defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes were defined as able to treat her/himself and plasma glucose below 3.1 mmol/L.

Time frame:
Week 0 to Week 26 + 7 days follow up
Reported as:
Number · Episodes/100 years of patient exposure
Rate of Confirmed Hypoglycaemic Episodes
Episodes/100 years of patient exposureIDegAsp SimpleIDegAsp Step Wise
Rate of Confirmed Hypoglycaemic Episodes326207
SecondaryRate of Nocturnal Confirmed Hypoglycaemic Episodes

Rate of nocturnal confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes were defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes were defined as able to treat her/himself and plasma glucose below 3.1 mmol/L. Nocturnal hypoglycaemic episodes were defined as occurring between 00:01 and 05:59 a.m.

Time frame:
Week 0 to Week 26 + 7 days follow up
Reported as:
Number · Episodes/100 years of patient exposure
Rate of Nocturnal Confirmed Hypoglycaemic Episodes
Episodes/100 years of patient exposureIDegAsp SimpleIDegAsp Step Wise
Rate of Nocturnal Confirmed Hypoglycaemic Episodes5241

Adverse events

Collected over The adverse events were collected in a time frame of 26 weeks + 7 days follow up.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IDegAsp Simple—1/134 (0.7%)20/134 (14.9%)
IDegAsp Step Wise—6/140 (4.3%)26/140 (18.6%)
Most frequent serious events
Most frequent serious events
EventIDegAsp SimpleIDegAsp Step Wise
Diverticular perforationGastrointestinal disorders1/1340/140
Rectal haemorrhageGastrointestinal disorders0/1341/140
CholelithiasisHepatobiliary disorders0/1341/140
GastroenteritisInfections and infestations0/1341/140
Facial bones fractureInjury, poisoning and procedural complications0/1341/140
Subcutaneous haematomaInjury, poisoning and procedural complications0/1341/140
Cerebral infarctionNervous system disorders0/1341/140
ConvulsionNervous system disorders0/1341/140
Dizziness posturalNervous system disorders0/1341/140
Thalamic infarctionNervous system disorders0/1341/140
Most frequent other events
Most frequent other events
EventIDegAsp SimpleIDegAsp Step Wise
Upper respiratory tract infectionInfections and infestations12/13415/140
NasopharyngitisInfections and infestations8/13411/140

Baseline characteristics

Age, Continuous
Age, Continuous(years)IDegAsp SimpleIDegAsp Step WiseTotal
Mean57.0 ± 9.455.8 ± 9.756.4 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)IDegAsp SimpleIDegAsp Step WiseTotal
Female5984143
Male7756133
Glycosylated haemoglobin (HbA1c)
Glycosylated haemoglobin (HbA1c)(percentage of glycosylated haemoglobin)IDegAsp SimpleIDegAsp Step WiseTotal
Mean8.3 ± 0.88.2 ± 0.88.3 ± 0.8
Fasting plasma glucose (FPG)
Fasting plasma glucose (FPG)(mmol/L)IDegAsp SimpleIDegAsp Step WiseTotal
Mean8.9 ± 2.49.0 ± 2.38.9 ± 2.4
09

Study locations

42 sites
  • Novo Nordisk Investigational Site
    Concord, California 94520-1926, United States
  • Novo Nordisk Investigational Site
    Los Angeles, California 90057, United States
  • Novo Nordisk Investigational Site
    Montclair, California 91763, United States
  • Novo Nordisk Investigational Site
    Palm Springs, California 92262, United States
  • Novo Nordisk Investigational Site
    Spring Valley, California 91978, United States
  • Novo Nordisk Investigational Site
    Jacksonville, Florida 32209-6511, United States
  • Novo Nordisk Investigational Site
    Jacksonville, Florida 32258, United States
  • Novo Nordisk Investigational Site
    Pembroke Pines, Florida 33027, United States
  • Novo Nordisk Investigational Site
    Crestview Hills, Kentucky 41017-3464, United States
  • Novo Nordisk Investigational Site
    Madisonville, Kentucky 42431, United States
  • Novo Nordisk Investigational Site
    Paducah, Kentucky 42003, United States
  • Novo Nordisk Investigational Site
    Hyattsville, Maryland 20782, United States
  • Novo Nordisk Investigational Site
    North East, Maryland 21901, United States
  • Novo Nordisk Investigational Site
    Detroit, Michigan 48235, United States
  • Novo Nordisk Investigational Site
    Troy, Michigan 48085-5524, United States
  • Novo Nordisk Investigational Site
    Eagan, Minnesota 55123, United States
  • Novo Nordisk Investigational Site
    Smithtown, New York 11787, United States
  • Novo Nordisk Investigational Site
    Asheboro, North Carolina 27203, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75230, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75246, United States
  • Novo Nordisk Investigational Site
    Houston, Texas 77070, United States
  • Novo Nordisk Investigational Site
    Lubbock, Texas 79423, United States
  • Novo Nordisk Investigational Site
    Sugar Land, Texas 77478, United States
  • Novo Nordisk Investigational Site
    Newport News, Virginia 23606, United States
  • Novo Nordisk Investigational Site
    Milwaukee, Wisconsin 53209, United States
  • Novo Nordisk Investigational Site
    Seoul, 08308, Korea, Republic of
  • Novo Nordisk Investigational Site
    Seoul, 110-746, Korea, Republic of
  • Novo Nordisk Investigational Site
    Seoul, 150-950, Korea, Republic of
  • Novo Nordisk Investigational Site
    Seoul, 158-710, Korea, Republic of
  • Novo Nordisk Investigational Site
    Suwon, 16247, Korea, Republic of
  • Novo Nordisk Investigational Site
    Johor Bahru, 80100, Malaysia
  • Novo Nordisk Investigational Site
    Kota Bharu, Kelantan, 16150, Malaysia
  • Novo Nordisk Investigational Site
    Selangor, 46150, Malaysia
  • Novo Nordisk Investigational Site
    Guadalajara, Jalisco 44650, Mexico
  • Novo Nordisk Investigational Site
    Monterrey, 64460, Mexico
  • Novo Nordisk Investigational Site
    Bayamon, 00961, Puerto Rico
  • Novo Nordisk Investigational Site
    Bangkok, 10400, Thailand
  • Novo Nordisk Investigational Site
    Nakhon Ratchasima, 30000, Thailand
  • Novo Nordisk Investigational Site
    Antalya, 07058, Turkey
  • Novo Nordisk Investigational Site
    Istanbul, 34096, Turkey
  • Novo Nordisk Investigational Site
    Istanbul, 34718, Turkey
  • Novo Nordisk Investigational Site
    Istanbul, 34890, Turkey
10

References and documents

Publications

  • Park SW, Bebakar WM, Hernandez PG, Macura S, Herslov ML, de la Rosa R. Insulin degludec/insulin aspart once daily in Type 2 diabetes: a comparison of simple or stepwise titration algorithms (BOOST(R) : SIMPLE USE). Diabet Med. 2017 Feb;34(2):174-179. doi: 10.1111/dme.13069. Epub 2016 Mar 6. PubMed 26773557 ↗
  • Yang W, Akhtar S, Franek E, Haluzik M, Hirose T, Kalyanam B, Kar S, Wu T, Gogas Yavuz D, Unnikrishnan AG. Postprandial Glucose Excursions in Asian Versus Non-Asian Patients with Type 2 Diabetes: A Post Hoc Analysis of Baseline Data from Phase 3 Randomised Controlled Trials of IDegAsp. Diabetes Ther. 2022 Feb;13(2):311-323. doi: 10.1007/s13300-021-01196-7. Epub 2022 Jan 19. PubMed 35044568 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2011, a primary completion of Apr 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2015, 3 years 7 months after primary completion. A results delay was requested in May 2012.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2011
First posted
Jun 3, 2011
Start
Jun 2011
Primary completionActual
Apr 2012
CompletionActual
Apr 2012
Results delay requested
May 9, 2012
Results first posted
Nov 20, 2015
Last update
Mar 17, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01365507
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jun 3, 2011
Start date
Jun 2011
Primary completion
Apr 2012
Completion
Apr 2012
Results posted
Nov 20, 2015
Last update
Mar 17, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin degludec · Insulin Aspart

Start the discussion